Gland Pharma Limited (NSE:GLAND)

Gland Pharma Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Revenue	57,290	56,647	36,246	44,007	34,629	26,332
Revenue Growth (YoY)	16.63%	56.29%	-17.64%	27.08%	31.51%	28.81%
Cost of Revenue	25,571	25,539	18,595	22,494	16,097	12,155
Gross Profit	31,720	31,108	17,651	21,513	18,532	14,178
Selling, General & Admin	13,897	12,668	4,047	3,397	3,122	2,784
Other Operating Expenses	4,808	4,895	3,271	3,009	2,385	1,823
Operating Expenses	22,666	21,223	8,807	7,513	6,498	5,569
Operating Income	9,053	9,885	8,844	14,000	12,034	8,609
Interest Expense	-400.98	-217.9	-62.87	-34.02	-29.11	-62.51
Interest & Investment Income	1,506	1,506	1,794	1,386	859.49	514.86
Currency Exchange Gain (Loss)	106.05	106.05	571.45	792.05	405.26	693.11
Other Non Operating Income (Expenses)	424.01	9.1	-1.07	-2.85	77.77	-0.6
EBT Excluding Unusual Items	10,689	11,288	11,146	16,142	13,348	9,754
Gain (Loss) on Sale of Investments	3.48	3.48	28.48	44.89	-	-
Gain (Loss) on Sale of Assets	2.49	2.49	-0.81	-1.78	0.24	173.93
Asset Writedown	-	-	-63.32	-	-	-
Other Unusual Items	-	-	-564.61	-	-	-
Pretax Income	10,726	11,325	10,546	16,186	13,348	9,929
Income Tax Expense	3,682	3,601	2,735	4,069	3,378	2,200
Net Income	7,044	7,725	7,810	12,117	9,970	7,729
Net Income to Common	7,044	7,725	7,810	12,117	9,970	7,729
Net Income Growth	6.93%	-1.10%	-35.54%	21.54%	29.00%	71.04%
Shares Outstanding (Basic)	165	165	165	164	158	155
Shares Outstanding (Diluted)	165	165	165	165	158	155
Shares Change (YoY)	0.01%	0.03%	0.09%	3.95%	2.15%	-
EPS (Basic)	42.76	46.90	47.44	73.81	63.07	49.88
EPS (Diluted)	42.76	46.89	47.43	73.64	62.99	49.88
EPS Growth	6.92%	-1.14%	-35.59%	16.91%	26.29%	71.05%
Free Cash Flow	-	6,069	1,430	2,794	3,762	5,063
Free Cash Flow Per Share	-	36.84	8.69	16.98	23.77	32.67
Dividend Per Share	-	20.000	-	-	-	-
Gross Margin	55.37%	54.92%	48.70%	48.89%	53.52%	53.84%
Operating Margin	15.80%	17.45%	24.40%	31.81%	34.75%	32.69%
Profit Margin	12.30%	13.64%	21.55%	27.53%	28.79%	29.35%
Free Cash Flow Margin	-	10.71%	3.95%	6.35%	10.86%	19.23%
EBITDA	13,648	13,138	10,310	15,102	13,020	9,553
EBITDA Margin	23.82%	23.19%	28.44%	34.32%	37.60%	36.28%
D&A For EBITDA	4,594	3,253	1,466	1,101	985.75	943.97
EBIT	9,053	9,885	8,844	14,000	12,034	8,609
EBIT Margin	15.80%	17.45%	24.40%	31.81%	34.75%	32.69%
Effective Tax Rate	34.32%	31.79%	25.94%	25.14%	25.31%	22.16%
Revenue as Reported	59,408	58,350	38,651	46,246	35,977	27,724

Source: S&P Capital IQ. Standard template. Financial Sources.